SLC5A2 and stage 5 chronic kidney disease: The current meta-analysis [22] showed that SGLT2 inhibitors reduced the risk of renal disease progression (including worsening eGFR, end-stage renal disease, or renal death) by 45%, with a similar benefit in those with and without atherosclerotic cardiovascular disease.